EZR and neoplasm: In the present study, we propose the use of a genetically modified oncolytic adenovirus coding for a human variant IL-2 cytokine, Ad5/3-E2F-d24-vIL2 (aka TILT-452), to enable efficient NK cell therapy anti-tumor response in human OvCa tumors.